RPG Life Sciences Limited - Asset Resilience Ratio
RPG Life Sciences Limited (RPGLIFE) has an Asset Resilience Ratio of 31.67% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RPG Life Sciences Limited debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2025)
This chart shows how RPG Life Sciences Limited's Asset Resilience Ratio has changed over time. See shareholders equity of RPG Life Sciences Limited for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down RPG Life Sciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see RPGLIFE company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs1.32 Billion | 18.68% |
| Short-term Investments | Rs917.20 Million | 13.0% |
| Total Liquid Assets | Rs2.24 Billion | 31.67% |
Asset Resilience Insights
- Very High Liquidity: RPG Life Sciences Limited maintains exceptional liquid asset reserves at 31.67% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
RPG Life Sciences Limited Industry Peers by Asset Resilience Ratio
Compare RPG Life Sciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for RPG Life Sciences Limited (2017–2025)
The table below shows the annual Asset Resilience Ratio data for RPG Life Sciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 39.81% | Rs2.62 Billion ≈ $28.32 Million |
Rs6.58 Billion ≈ $71.14 Million |
+15.80pp |
| 2024-03-31 | 24.01% | Rs1.23 Billion ≈ $13.32 Million |
Rs5.13 Billion ≈ $55.46 Million |
-5.13pp |
| 2023-03-31 | 29.14% | Rs1.22 Billion ≈ $13.22 Million |
Rs4.19 Billion ≈ $45.35 Million |
+25.41pp |
| 2022-03-31 | 3.73% | Rs128.60 Million ≈ $1.39 Million |
Rs3.45 Billion ≈ $37.27 Million |
+3.23pp |
| 2021-03-31 | 0.50% | Rs15.30 Million ≈ $165.46K |
Rs3.03 Billion ≈ $32.81 Million |
+0.46pp |
| 2020-03-31 | 0.04% | Rs1.20 Million ≈ $12.98K |
Rs2.67 Billion ≈ $28.85 Million |
0.00pp |
| 2019-03-31 | 0.05% | Rs1.20 Million ≈ $12.98K |
Rs2.51 Billion ≈ $27.17 Million |
-0.24pp |
| 2018-03-31 | 0.28% | Rs8.30 Million ≈ $89.76K |
Rs2.91 Billion ≈ $31.50 Million |
+0.08pp |
| 2017-03-31 | 0.20% | Rs5.00 Million ≈ $54.07K |
Rs2.46 Billion ≈ $26.63 Million |
-- |
About RPG Life Sciences Limited
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. … Read more